Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation

Transplant Immunology

Volumn 23, Issue 3, 2010, Pages 93-103

  Dandel, Michael ^a   Lehmkuhl, Hans Brendan ^a   Knosalla, Christoph ^a   Hetzer, Roland ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Drug toxicity; Heart transplantation; Immunosuppression; Outcome; Rejection

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADRENAL INSUFFICIENCY; ALOPECIA; ANEMIA; ARTERY DISEASE; BACTERIAL INFECTION; BONE GROWTH; BONE MARROW SUPPRESSION; CANCER RISK; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR DISEASE; CATARACT; CHOLESTASIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DONOR SELECTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; ENDOTHELIUM INJURY; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT FAILURE; HEART FAILURE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG TOXICITY; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MENTAL INSTABILITY; METABOLIC DISORDER; MYCOSIS; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; ORGAN PRESERVATION; OSTEOPENIA; OSTEOPOROSIS; PHARMACODYNAMICS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; REVIEW; SIDE EFFECT; SODIUM RETENTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WATER RETENTION; WOUND HEALING IMPAIRMENT;

ANIMALS; CALCINEURIN; CLINICAL PROTOCOLS; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HEPATIC INSUFFICIENCY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEUROTOXICITY SYNDROMES; RENAL INSUFFICIENCY; TIME FACTORS;

EID: 77953913455     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.04.007     Document Type: Review

References (89)

1. Halloran P.F., Gourishankar S. Principles and overview of immunosuppression. Primer on Transplantation. American Society of Transplantation 2001, 87-98. D.J. Norman, L.A. Turka (Eds.).
2. Lindenfeld J.A., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., et al. Drug therapy in the heart transplant recipient: Part II: Immunosuppressive Drugs. Circulation 2004, 110:3858-3865.
3. Mourad M., Wallemacq P., De Meyer M., Malaise J., De Pauw L., Eddour D.C., et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008, 85(7 Suppl):S19-S24.
4. O'Neill J.O., Edwards L.B., Taylor D.O. Myocophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the Transplant Registry of the ISHLT. J Heart Lung Transplant 2006, 25:1186-1191.
5. Crespo-Leiro M.G., Alonso-Pulpon N., Arizon J.M., Delgado J.F., Palomo J., Manito J., et al. Influence of induction therapy immunosuppressive regimen and ant-viral prophylaxis on development of lymphomas after heart transplantation: Data from the Spanish Post-Heart Transplant Tumor Registry. J Heart Lung Transplant 2007, 26:1105-1109.
6. Taylor D.O., Edwards L.B., Aurora P., Dobbels F., Kirk R., Rahmel A.O., et al. Registry of the International Society for Heart and Lung Transplantation: 25th official adult heart transplant report:2008. J Heart Lung Transplant 2008, 27:943-956.
7. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., Dries D.L., Kaiser P.A., Hynan L.S., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005, 24(9):1327-1331.
8. Hersberger R.E., Starling R.C., Eisen H.J., Bergh C.H., Kormos R.L., Love R.B., Van Bakel A., et al. Daclizumab to prevent rejection after heart transplantation. N Engl J Med 2005, 352(26):2705-2713.
9. Flaman F., Zieroth S., Rao V., Ross H., Delgado D.H. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Transplant 2006, 25(11):1358-1362.
10. Segovia J., Rodriguez-Lambert J.L., Crespo-Leiro M.G., Almenar L., Roig R., Gómez-Sánchez M.A., et al. A randomized multicenter comparison of basiliximab and muronomab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006, 81(11):1542-1548.
11. Zhang R., Haverich A., Strüber M., Simon A., Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant 2008, 27:603-609.
12. Mastrobuoni S., Ubilla M., Cordero A., Herreros J., Rabago G. Two-dose daclizumab, tacrolimus, mycophenolate mofetil and steroid free regimen in de novo cardiac recipients: early experience. Transplant Proc 2007, 39(7):2163-2166.
13. Nankivell B.J., Wavamunno M.D., Borrows R.J., Vitalone M., Fung C.L., Allen R.D., et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007, 7:366-376.
14. Reichart B., Meiser B., Viganó M., Rinaldi M., Martinelli L., Yacoub M., et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998, 17(8):775-781.
15. Taylor D.O., Barr M.L., Radovanevic B., Renlund D.G., Mentzer R.M.Jr, Smart F.W., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999, 18(4):336-345.
16. Grimm M., Rinaldi M., Yonan N.A., Arpesella G., Arizón Del Prado J.M., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006, 6:1387-1397.
17. Hunt S.A., Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008, 52:587-588.
18. Lubitz S.A., Baran D.A., Alwarshetty M.M., Pinney S., Kaplan S., et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 2006, 25:699-706.
19. Eisen H.J., Kobashigawa J. Keogh, Bourge R, Renlund D, Mentzer R. et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005, 24:517-525.
20. Dandel M., Jasaityte R., Lehmkuhl H., Knosalla C., Hetzer R. Maintenance immuno-suppression with mycophenolate mofetil:Long-term efficacy and safety. Transplant Proc 2009, 41(6):2585-2588.
21. Kaczmarek I., Ertl B., Schmauss D., Sadoni S., Knez A., Daebritz S., et al. Preventing cardiac allograft vasculopathy: Long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006, 25:550-556.
22. Kobashigawa J., Miller L., Renlund D., Mentzer R., Alderman E., Bourge R. A randomized active-controlled trial of myocophenolate mofetil in heart transplant recipients. Myocophenolate Mofetil Investigators. Transplantation 1998, 66(4):507-515.
23. Hamour I.M., Lyster H.S., Burke M.M., Rose M.L., Banner N.R. Myocophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplanted patients. Transplantation 2007, 83:570-576.
24. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation 2005, 79:S45-S46.
25. Dandel M. Immunosuppression and Long-Term Outcome after Heart Transplantation. Thorac Cardiovasc Surg 2009, 57(S 02):S148-S150.
26. Meiser B.M., Groetzner J., Kaczmarek I., Landwehr P., Müller M., Jung S., et al. Tacrolimus or cyclosporine: Which is the better partner or mycophenolate mofetil in heart transplant recipients. Transplantation 2004, 78:591-598.
27. Mamelok L. From mechanisms to long-term benefits. Transplantation 2005, 79:S43-S44.
28. Kobashigawa J., Tobis J.M., Mentzer R.M., Valantine H.A., Bourge R.C., Mehra M.R., et al. Myocophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial. Am J Transplant 2006, 6:993-997.
29. Schmauss D., Weis M. Cardiac allograft vasculopathy. Recent developments. Circulation 2008, 117:2131-2141.
30. Eisen H.J., Tuzcu M., Dorent R., Kobashigawa J., Mancini D., Valantine H.A., et al. Everolimus for prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003, 349:847-858.
31. Vigano M., Tuzcu M., Benza R., Boissonnat P., Haverich A., Hill J., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24 month analysis. J Heart Lung Transplant 2007, 26(6):584-592.
32. Haddad F., Deuse T., Pham M., Khazanie P., Rosso F., Luikart H., et al. Changing trends in infectious disease in heart transplantation. Heart Lung Transplant 2010 Mar, 29(3):306-315. (Epub 2009 Oct 22).
33. Crespo-Leiro M.G. Calcineurin inhibitors in heart transplantation. Transplant Proc 2005, 37:4018-4020.
34. Hosenpud J.D., Bennet L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the joint UNOS/ISHLT Thoracic Registry. Transplantation 2001, 72:1662-1665.
35. Ye F., Ying-Bin X., Yu-Guo W., Hetzer R. Tacrolimus vs. cyclosporine microemulsions for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009, 28(1):58-66.
36. Kobashigawa J.A., Miller L.W., Ewald Russel S.D., GA Zucker M.J., Goldberg L.R., et al. Tacrolimus with myocophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1 year report. Am J Transplant 2006, 6:1377-1386.
37. Hill J.A., Hummel M., Starling R.C., Kobashigawa J.A., Perrone S.V., Arizón J.M., et al. A lower incidence of cytomegalovirus in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84(11):1436-1442.
38. Zuckermann A.O., Aliabadi A.Z. Calcineurin-inhibitor minimization after heart transplantation. Transpl Int 2009, 22(1):78-89.
39. Lehmkuhl H.B., Mai D., Dandel M., Knosalla C., Hiemann N.E., Grauhan O., et al. Observational study with Everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007, 26:700-704.
40. Raichlin E., Bae J.-H., Khalpey Z., Edwards B.S., Kremers W.K., Clavell A.L., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007, 116:2726-2733.
41. Raichlin E., Kushwaha S.S. Proliferation signal inhibitors and cardiac vasculopathy. Curr Opin Organ Transplant 2008, 13(5):543-550.
42. Kupahally S., Al-Khaldy H., Weisshaar D., Valantine H.A., Oyer P., Robbins R.C., et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006, 6:986-992.
43. Ojo O.A., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a non-renal organ. N Engl J Med 2003, 349:931-940.
44. Flechner S.M., Kobashigawa J., Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transpl 2008, 22:1-15.
45. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007, 26(6):557-564.
46. Lyster H., Paniker G., Leaver N., Banner N.R. Initial experience with sirolimus and mucophenolate mofetil for renal rescue from cyclosporine nephrotoxicitys after heart transplantation. Tranplant Proc 2004, 36:3167-3170.
47. Bestetti R., Theodoropoulos T.A., Burdmann E.A., Filho M.A., Cordeiro J.A., Villafanha D. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the mid-term follow-up. Transplantation 2006, 81(5):692-696.
48. Zuckermann A., Manito N., Epailly E., Fiane A., Bara C., Delgado J.F., et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008, 27:141-149.
49. Baryalei M., Zenker D., Pieske, Tondo H., Dalichau H., Aleksik I. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003, 35(4):1539-1542.
50. Schweiger M., Wasler A., Prenner G., Stiegler P., Stadlbauer V., Schwarz M., et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006, 16:46-51.
51. Störk S., Angermann C.E., Costard-Jäckle A., Siebert U., Dengler T.J., Tenderich G., et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients.- The IMPROVED multi-center study. Eur Heart J 2004, 25:1626-1634.
52. Zuckermann A., Ploner M., Keziban U. Benefit of mycophenolate mophetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation. J Heart Lung Transplant Int 2001, 20:163.
53. Vitko S., Margreiter R., Weimar W., Dantal J., Kuypers D., Winkler M., et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005, 5:2521-2530.
54. Chamorro C.I., Almenar L., Martinez-Dolz L., Sánchez-Lacuesta E., Martín-Pastor J., Ten-Morro F., et al. Do cardiovascular risk factors influence cardiac allograft vasculopathy?. Transplant Proc 2006, 38:2572-2574.
55. Kobashigawa J.A., Starling R.C., Mehra M.R., Kormos R.L., Bhat G., Barr M.L., et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006, 25:1063-1069.
56. Abdel-Fattah G., Morrisett J.D., Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003, 35(Suppl 3A):143S.
57. Kobashigawa J.A., Patel J., Furukawa H., Moriguchi J.D., Yeatman L., Takemoto S., et al. Five-year results of a randomized, single-center study of tacrolimus vs. microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006, 25:434-439.
58. Aliabadi A.Z., Zuckermann A.O., Grimm M. Immunosuppressive Therapy in older cardiac transplant patients. Drugs Aging 2007, 24(11):913-932.
59. Roche S.L., Kaufmann J., Dipchand A.I., Kantor P.F. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant 2008, 27(5):501-507.
60. Aleksic I., Baryalei M., Busch T., Pieske B., Schorn B., Strauch J., et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000, 69:1586-1590.
61. Tedoriya T., Keogh A.M., Kusano K., Savdie E., Hayward C., Spratt P.M., et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation - Potential role of mycophenolate mofetil. J Heart Lung Transplant 2002, 21:976-982.
62. Sanchez V., Delgado J.F., Morales J.M. Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004, 36:2823-2825.
63. Boyer O., Le Bidois J., Dechaux M., Gubler M.C., Niaudet P. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005, 79:1405-1410.
64. Manito N., Kaplinsky E.J., Roca J., Castells E., Saura E., Gomez-Hospital J.A., et al. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin Transpl 2005, 19:304-308.
65. Al-Aly Z., Sachdeva A., Philoctete Ashley JM Bastani B. Preliminary experience with mycophenolate mophetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology 2006, 11:151-155.
66. Cantarovich M. Renal protective strategies in heart transplant patients. Curr Opin Cardiol 2007, 22:133-138.
67. Ross H., Pflugfelder P., Haddad H., Cantarovich M., White M., Ignaszewski A., et al. Cyclosporine reduction in the presence of everolimus: 3 months data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008, 27(5):197-202.
68. Ross H., Pfugfelder P., Haddad H., Cantarovich M., White M., Ignaszewski A., et al. Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. Transpl Int 2010, 23(1):31-37.
69. Gullestad L., Iversen M., Mortensen S.-A., Eiskjaer H., Riise G.C., Mared L., et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter randomized trial. Transplantation 2010 Apr 15, 89(7):864-872.
70. Meiser B., Kaczmarek I., Mueller M., Groetzner J., Weis M., Knez A., et al. Low-dose tacrolimus/sirolimus withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 2007, 26:598-603.
71. Lehmkuhl H.B., Arizon J., Vigano M., Almenar L., Gerosa G., Maccherini M., et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009, 88:115-122.
72. Patel J., Kobashigawa J.A. Minimization of immunosuppression: transplant immunology. Transpl Immunol 2008, 20(1-2):48-54.
73. Tredger J.M., Brown N.W., Dhawan A. Calcineurin inhibitor sparing in paediatric solid organ Transplantation: managing the efficacy/toxicity conundrum. Drugs 2008, 68(10):1385-1414.
74. Gude E., Gullestad L., Arora S., Simonsen S., Hoel I., Hartmann A., et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010 Mar 19, [Epub ahead of print].
75. Groetzner J., Meiser B., Landwehr P., Buehse L., Müller M., Kaczmarek I., et al. Mycophenolate mofetil and sirolimus as calcineurin-inhibitor free immunosuppression for late cardiac transplant recipients with chronic renal failure. Transplantation 2004, 77(4):568-574.
76. Kushwaha S.S., Khalpey Z., Frantz L.P., Rodeheffer R.J., Clavell A.L., Daly R.C., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in cacineurin-induced nephrotoxicity. J Heart Lung Transplant 2005, 24:2129-2136.
77. Groetzner J., Kaczmarek I., Schulz U., Stegemann E., Kaiser K., Wittwer T., et al. Mycophenolate and sirolimus as CNI-free immunosuppression improves renal function better than CNI-reduction in late cardiac transplant recipients with chronic heart failure. Transplantation 2009, 87(5):726-733.
78. Rothenburger M., Zuckermann A., Bara C., Hummel M., Strüber M., Hirt S., et al. Recommendations for the use of everolimus (Certican) in heart transplantation: Results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007, 26:305-311.
79. Meiser B., Reichhart B., Adamidis I., Uberfuhr P., Kaczmarek I., et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following heart transplantation. Am J Transplant 2005, 1:827-831.
80. Leet A.S., Bergin P.J., Richardson M., Taylor A.J., Esmore D., Kaye D.M. Outcomes following de novo CNI-free immunosuppression after heart transplantation: A single center experience. Am J Transplant 2009, 9(1):140-148.
81. Roche S.L., Kaufmann J., Dipchand J., Kantor P.F. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant 2008, 27(5):501-507.
82. Crespo-Leiro M., Delgado J., Almenar L., Arizón J.M., Blasco T., Brossa V., et al. Steroid use in transplant patients in Spain in the current era: A multcenter Survey. Transplant Proc 2009, 41(6):2244-2246.
83. Kobashigawa J.A., Stevenson L.W., Brownfield E.D., Moriguchi J.D., Kawata N., Fandrich R., et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 1992, 11:428-430.
84. Miller L.W., Wolford T., McBride L.R., Peigh P., Pennington D.G. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992, 11:431-434.
85. Leonard H.C., O'Sullivan J.J., Dark J.H. Long-term follow-up of pediatric cardiac transplant recipients on a steroid-free regime: role of endomyocardial biopsy. J Heart Lung Transplant 2000, 19:469-472.
86. Leonard H., Hornung T., Parry G., Dark J.H., et al. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediat Transplant 2003, 7:59-63.
87. Singh P.T., Faber C., Blume E.D., Worley S., Almond C.S., Smoot L.B., et al. Safety and early outcomes using corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. J Heart Lung Transplant 2010 May, 29(5):517-522.
88. Yamani M.H., Taylor D.O., Czerr J., Haire C., Kring R., Zhou L., et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transpl 2008, 22:76-81.
89. Keogh A., Richardson M., Ruygrok P. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease. Circulation 2004, 110:2694-2700.